SYS6090 combination therapy for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug, SYS6090, combined with other treatments for advanced non-small cell or small cell lung cancer that has spread and can't be removed by surgery. It aims to see if this combination can help shrink or control the cancer, and how safe it is for patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with advanced non-small cell lung cancer (NSCLC) that has spread to the chest or other parts of the body, or extensive-stage small cell lung cancer (SCLC), and it can't be treated with surgery or radiation.
- You are between 18 and 75 years old.
- You have at least one tumor that can be measured with imaging (like CT or MRI).
- You are in good physical condition (ECOG performance status of 0 or 1), meaning you can carry out daily activities.
- Your bone marrow and organ function are adequate (you have enough blood cells, and your liver and kidneys are working well).
- You do not have active brain metastases, or you have treated brain metastases that are stable and you don't need ongoing steroids or seizure medication.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment that combines a drug called SYS6010 with an immunotherapy (Enlonstobart) compared to the usual immunotherapy plus chemo for advanced lung cancer. The goal is to see if this combo works better and helps people with PD-L1 positive lung cancer live longer and feel better.
This trial tests a new drug called SYS6040 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective.
This trial compares a new drug called SYS6010 to a standard chemotherapy drug (docetaxel) for people with advanced non-small cell lung cancer that has not responded to previous treatments. The goal is to see if the new drug works better or has fewer side effects.
This trial tests whether giving an experimental drug (SYS6010) together with an immunotherapy (a type of treatment that helps your immune system fight cancer) after surgery can lower the chance of cancer coming back. It's for people with non-small cell lung cancer that was completely removed but didn't respond very well to surgery alone.
This study tests a new combination of drugs (SYHX2011, carboplatin, and an immunotherapy called enlonstobart) as the first treatment for advanced squamous lung cancer that is PD-L1 positive. The goal is to see if this combination helps shrink tumors and slow cancer growth.
This trial tests whether adding a new drug (SYS6010) to the standard targeted therapy osimertinib before surgery can help shrink EGFR-positive lung tumors more than osimertinib alone. It is for people with early-stage (II to IIIB) non-small cell lung cancer that can be removed surgically.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.